Tumor-targeting properties of 90Y- and 177Lu-labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model

Nuclear Medicine and Biology

Volumn 32, Issue 5, 2005, Pages 485-493

  Miao, Yubin ^a,b   Hoffman, Timothy J ^a,b   Quinn, Thomas P ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

MSH peptide; 90Y and 177Lu; Melanoma targeting and therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID RHENIUM (11 ARGINYL)CYSTEINYLCYSTEINYLMETHIONYLSERYLHISTIDINE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID RHENIUM (11 ARGINYL)CYSTEINYLCYSTEINYLMETHIONYLSERYLHISTIDINE Y 90; LUTETIUM; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL TRANSPORT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG RETENTION; DRUG TARGETING; DRUG UPTAKE; FEMALE; IN VITRO STUDY; KIDNEY; MELANOMA; MELANOMA CELL; MOUSE; MOUSE STRAIN; NONHUMAN;

ALPHA-MSH; ANIMALS; FEMALE; LUTETIUM; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 20744450775     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2005.03.007     Document Type: Article

References (40)

1. C.J. Anderson, L.A. Jones, L.A. Bass, E.L. Sherman, D.W. McCarthy, and P.D. Cutler Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats J Nucl Med 39 1998 1944 1951
2. 3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model Clin Cancer Res 5 1999 3608 3616
3. 3-octreotide Eur J Nucl Med 28 2001 426 434
4. M. De Jong, R. Valkema, F. Jamar, L.K. Kvols, D.J. Kwekkeboom, and W.A.P. Breeman Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings Semin Nucl Med 32 2002 133 140
5. A. Heppeler, S. Froidevaux, A.N. Eberle, and H.R. Maecke Receptor targeting for tumor localization and therapy with radiopeptides Curr Med Chem 7 2000 971 994
6. W.A. Volkert, W.F. Goeckeler, G.J. Ehrhardt, and A.R. Ketring Therapeutic radionuclides: production and decay property consideration J Nucl Med 32 1991 174 185
7. A. Otte, E. Jermann, M. Behe, M. Goetze, H.C. Bucher, and H.W. Roser A powerful new tool for receptor-mediated radionuclide therapy Eur J Nucl Med 24 1997 792 795
8. A. Otte, J. Mueller-Brand, S. Dellas, E.U. Nitzsche, R. Herrmann, and H.R. Maecke Yttrium-90-labelled somatostatin-analogue for cancer treatment Lancet 351 1998 417 418
9. P.O. Zamora, H. Bender, S. Gulhke, M.J. Marek, F.F. Knapp Jr., and B.A. Rhodes Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy Anticancer Res 17 1997 1803 1808
10. 3]octreotate for somatostatin receptor-targeted radionuclide therapy Int J Cancer 92 2001 628 633
11. J.E. Freitas, M.D. Gross, S. Ripley, and B. Shapiro Radionuclide diagnosis and therapy of thyroid cancer: current status report Semin Nucl Med 15 1985 106 131
12. C.A. Hoefnagel Radionuclide therapy revisited Eur J Nucl Med 18 1991 408 431
13. M.F. Giblin, N.N. Wang, T.J. Hoffman, S.S. Jurisson, and T.P. Quinn Design and characterization of α-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination Proc Natl Acad Sci U S A 95 1998 12814 12818
14. 99mTechnetium-labeled cyclic α-melanocyte-stimulating hormone peptide analogues Cancer Res 60 2000 5649 5658
15. 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy Int J Cancer 101 2002 480 487
16. Y. Miao, D. Whitener, W. Feng, N.K. Owen, J. Chen, and T.P. Quinn Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues Bioconjug Chem 14 2003 1177 1184
17. 188Re labeled α-melanocyte stimulating hormone peptide analogue in murine and human melanoma-bearing mouse models J Nucl Med 46 2005 121 129
18. 213Bi, and their decay chain related radionuclides, for therapeutic applications Chem Rev 101 2001 2019 2036
19. 90Y-SMT 487) eradicates experimental rat pancreatic CA20948 tumors Eur J Nucl Med 25 1998 668 674
20. 3-octreotate in tumor-bearing rats Nucl Med Biol 28 2001 327 334
21. E. Horak, F. Hartmann, K. Garmestani, C. Wu, M.W. Brechbiel, and O.A. Gansow Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1 J Nucl Med 38 1997 1944 1950
22. C.S. Cutler, C.J. Smith, G.J. Ehrhardt, T.T. Tyler, S.S. Jurisson, and E. Deutsch Current and potential therapeutic used of lanthanide radioisotopes Cancer Biother Radiopharm 15 2000 531 545
23. 3] octreotate in a rat liver micrometastases model Int J Cancer 104 2003 376 379
24. 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties J Nucl Med 42 2001 1847 1855
25. D.J. Hnatowich, F. Virzi, and P.W. Doherty DTPA-coupled antibodies labeled with yttrium-90 J Nucl Med 26 1985 503 509
26. C.M. Anderson, and A.C. Buzaid Systematic treatments for advanced cutaneous melanoma Oncology 9 1995 1149 1158
27. 111In-labeled DOTA-conjugated rhenium-cyclized α-MSH analogues J Med Chem 45 2002 3048 3056
28. 3]-octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size J Nucl Med 42 2001 1841 1846
29. 90Y-DOTATOC in association with amino acid infusion: a phase I study Eur J Nucl Med Mol Imaging 30 2003 207 216
30. W.A. Volkert, and T.J. Hoffman Therapeutic radiopharmaceuticals Chem Rev 99 1999 2269 2292
31. 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution J Nucl Med 40 1999 268 276
32. A. Heppler, S. Froidevaux, H.R. Mäcke, E. Jermann, M. Béhé, and P. Powell Radiometal-labeled macrocyclic chelator-derived somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal therapy Chem Eur J 5 1999 1974 1981
33. 111In-labeled DOTA-biomolecule conjugates Bioconjug Chem 13 2002 902 913
34. 90Y-labeled analogue Eur J Nucl Med 26 1999 358 366
35. C.E. Mørgenson, and K. Sølling Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids Scand J Clin Lab Invest 37 1977 477 486
36. S. Silbernagl The renal handling of amino acids and oligopeptides Physiol Rev 68 1988 912 986
37. T. Maack, V. Johnson, S.T. Kan, J. Figueiredo, and D. Sigulem Renal filtration, transport, and metabolism of low molecular weight proteins: a review Kidney Int 16 1979 251 270
38. L.A. Bass, M.V. Lanahan, J.R. Duncan, J.L. Erion, A. Srinivasan, and M.A. Schmidt Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-d-Phe1-octreotide Bioconjug Chem 9 1998 192 200
39. S. Froidevaux, M. Calame-Christe, J. Schuhmacher, H. Tanner, R. Saffrich, and M. Henze A gallium-labeled DOTA-α-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases J Nucl Med 45 2004 116 123
40. 177Lu labeled alpha-melanocyte stimulating hormone peptide analogue through coupling a negatively charged amino acid to N-terminus of the peptide J Nucl Med 45 Suppl 2004 52